<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508469</url>
  </required_header>
  <id_info>
    <org_study_id>EMD-06-03</org_study_id>
    <nct_id>NCT00508469</nct_id>
  </id_info>
  <brief_title>Adherence Assessment With Travalert Dosing Aid</brief_title>
  <official_title>Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare adherence in patients on a fixed combination of
      travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004%
      and timolol 0.5% using the Travalert® device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence</measure>
    <time_frame>6 months</time_frame>
    <description>Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travalert with travoprost/timolol fixed combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travalert with travoprost and timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)</intervention_name>
    <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
    <arm_group_label>Travalert with travoprost/timolol fixed combination</arm_group_label>
    <other_name>DuoTrav®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004% eye drops</intervention_name>
    <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
    <arm_group_label>Travalert with travoprost and timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol 0.05% eye drops</intervention_name>
    <description>One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.</description>
    <arm_group_label>Travalert with travoprost and timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Travalert Dosing Aid</intervention_name>
    <description>Approved device used with study medication to record time of instillation and quantify dosing</description>
    <arm_group_label>Travalert with travoprost/timolol fixed combination</arm_group_label>
    <arm_group_label>Travalert with travoprost and timolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of open-angle glaucoma or ocular hypertension;

          -  Inadequate control with beta-blocker or prostaglandin monotherapy and starting therapy
             with travoprost 0.004% and timolol 0.05%;

          -  Intraocular pressure (IOP) at the screening visit in at least one eye ≥ 19 mmHg but
             not exceeding 36 mmHg in either eye;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential currently pregnant, breastfeeding, or not taking
             control measures to prevent pregnancy;

          -  Not currently receiving treatment for lowering IOP with beta-blockers or prostaglandin
             analogs;

          -  Currently on therapy or was in therapy with another investigational agent within 30
             days prior to the baseline visit;

          -  History of chronic or recurrent severe inflammatory eye disease, or history of ocular
             trauma within the past six (6) months, or history of ocular infection or ocular
             inflammation within the past three (3) months in either eye;

          -  History of clinically significant or progressive retinal disease or history of any
             other severe ocular pathology in either eye that would preclude the administration of
             a topical prostaglandin analogue;

          -  History of severe or serious hypersensitivity to prostaglandin drugs or their
             analogues, to topical or systemic beta-blockers, or to any components of the study
             medication;

          -  Intraocular surgery within the past six (6) months or ocular laser surgery within the
             past three (3) months as determined by patient history and/or examination in either
             eye;

          -  Any abnormality preventing reliable applanation tonometry of either eye;

          -  Best-corrected visual acuity worse than 20/30 Snellen in either eye;

          -  Use of any additional topical or systemic ocular hyposensitive medication during the
             study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Francisco M. Honrubia</last_name>
    <role>Study Director</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <results_first_submitted>June 8, 2012</results_first_submitted>
  <results_first_submitted_qc>June 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2012</results_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular pressure</keyword>
  <keyword>Open-angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>Adherence</keyword>
  <keyword>Compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 5 hospitals in Spain.</recruitment_details>
      <pre_assignment_details>Baseline characteristics are presented for the per-protocol population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Travalert With Travoprost/Timolol Fixed Combination</title>
          <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
        </group>
        <group group_id="P2">
          <title>Travalert With Travoprost and Timolol</title>
          <description>One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Travalert With Travoprost/Timolol Fixed Combination</title>
          <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
        </group>
        <group group_id="B2">
          <title>Travalert With Travoprost and Timolol</title>
          <description>One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="11.1"/>
                    <measurement group_id="B2" value="68.6" spread="11.8"/>
                    <measurement group_id="B3" value="66.2" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence</title>
        <description>Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.</description>
        <time_frame>6 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Travalert With Travoprost/Timolol Fixed Combination</title>
            <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
          </group>
          <group group_id="O2">
            <title>Travalert With Travoprost and Timolol</title>
            <description>One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>Patients were considered adherent if a minimum of 80% of their instillations were administered ±2 hours of the scheduled time.</description>
          <population>Per protocol</population>
          <units>percentage of adherent patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study: 2 years, 3 months.</time_frame>
      <desc>The safety population includes all enrolled patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Travalert With Travoprost/Timolol Fixed Combination</title>
          <description>One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.</description>
        </group>
        <group group_id="E2">
          <title>Travalert With Travoprost and Timolol</title>
          <description>One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Brachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Severine Durier, PharmD</name_or_title>
      <organization>Alcon France</organization>
      <phone>+33 1 47 10 48 43</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

